VolitionRx Limited
General ticker "VNRX" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $45.7M (TTM average)
VolitionRx Limited does not follow the US Stock Market performance with the rate: -31.5%.
Estimated limits based on current volatility of 13.1%: low 0.37$, high 0.48$
Factors to consider:
- Total employees count: 75 (-11.8%) as of 2025
- Top business risk factors: Inability to achieve profitability, Insufficient capital, Going concern doubt, Market acceptance, Regulatory and compliance
- Current price 88.3% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.23$, 9.84$]
- 2026-12-31 to 2027-12-31 estimated range: [2.18$, 6.90$]
Financial Metrics affecting the VNRX estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -72.84 <= 0.28
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.33 > -0.64
- Positive: Interest expense per share per price, % of 1.97 <= 3.34
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0.16 <= 0.27
- Negative: Shareholder equity ratio, % of -496.24 <= 18.97
Short-term VNRX quotes
Long-term VNRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.78MM | $1.23MM | $1.73MM |
| Operating Expenses | $36.76MM | $28.26MM | $23.47MM |
| Operating Income | $-35.99MM | $-27.02MM | $-21.74MM |
| Non-Operating Income | $0.31MM | $-0.23MM | $-1.76MM |
| Interest Expense | $0.22MM | $0.34MM | $0.53MM |
| R&D Expense | $19.55MM | $14.41MM | $10.08MM |
| Income(Loss) | $-35.68MM | $-27.26MM | $-23.50MM |
| Net Income(Loss)* | $-35.68MM | $-26.97MM | $-23.50MM |
| Stockholders Equity | $-7.80MM | $-24.91MM | $-34.25MM |
| Assets | $27.95MM | $9.40MM | $6.90MM |
| Operating Cash Flow | $-18.06MM | $-25.89MM | $-19.68MM |
| Capital expenditure | $1.08MM | $0.57MM | $0.09MM |
| Investing Cash Flow | $-1.08MM | $-0.57MM | $-0.09MM |
| Financing Cash Flow | $28.98MM | $8.66MM | $17.09MM |
| Earnings Per Share** | $-10.02 | $-6.23 | $-4.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.